Kingston Health Sciences Centre
Kingston, Ontario, K7L3C9, Canada
Location status: Recruiting
Location contact
J G Boyd, MD, PhD
CONTACT
Tasha Jawa, MSc.
CONTACT
NCT Number: NCT04722939
Introduction. Initiation of acute kidney replacement therapy (KRT) is common in critically ill adults admitted to the intensive care unit (ICU), and is associated with increased morbidity and mortality. KRT has been linked to poor neurocognitive outcomes, leading to a reduced quality of life, as well as increased utilization of healthcare resources. Adults initiated on dialysis in the ICU may be particularly at risk of neurocognitive impairment, as survivors of critical illness are already predisposed to developing cerebrovascular disease and cognitive dysfunction over the long-term relative to healthy controls. Regional cerebral oxygen saturation (rSO2) may provide a critical early marker of long-term neurocognitive impairment in patients in this population. The INCOGNITO-AKI study aims to understand cerebral oxygenation in patients undergoing KRT, either continuous or intermittent, in the ICU. These findings will be correlated with long-term cognitive and functional outcomes, as well as structural brain pathology.
Methods and analysis. 108 patients scheduled to undergo treatment for acute kidney injury with KRT in the Kingston Health Sciences Centre ICU will be recruited into this prospective observational study. Enrolled patients will be assessed with intradialytic cerebral oximetry using near infrared spectroscopy (NIRS). Delirium will be assessed daily with the Confusion Assessment Method-Intensive Care Unit (CAM-ICU) and delirium severity quantified as cumulative CAM-ICU-7 scores. Neurocognitive impairment will be assessed at 3- and 12-months after hospital discharge using the Kinarm and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Structural brain pathology on MRI will also be measured at the same timepoints. Driving safety, adverse events, and medication adherence will be assessed at 12-months to evaluate the impact of neurocognitive impairment on functional outcomes.
Ethics and dissemination. This study has been approved by the Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (Approval number: DMED-2424-20). Results will be presented at critical care scientific conferences and a lay summary will be provided to patients and families in their preferred format.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Kingston, Ontario, K7L3C9, Canada
Location status: Recruiting
J G Boyd, MD, PhD
CONTACT
Tasha Jawa, MSc.
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cerebral oxygenation will be monitored with the FORESIGHT Elite cerebral oximeter during the first 72h of critical illness, and during subsequent hemodialysis sessions
Time frame: Patients will be screened daily in the ICU with the CAM-ICU-7 score up until the date of ICU discharge or day 30 of ICU stay.
Delirium severity will be calculated from the cumulated Confusion Assessment Method-Intensive Care Unit-7 (CAM-ICU-7) score
Time frame: 3 months and 12 months
Patients will undergo a neurocognitive battery with the Kinarm robot and Kinarm standardized tests.
Time frame: 3 months and 12 months
Patients will undergo assessment with the RBANS administered by a trained researcher.
Time frame: 12 months
Medication adherence will be assessed with the Medication Adherence Rating Scale (MARS)
Time frame: 12 months
Driving safety will be assessed by number of motor vehicle accidents.
Time frame: 12 months
Driving safety will be assessed by and the Manchester Driver Behavior Questionnaire
Time frame: Within 12 months of hospital discharge.
We will measure emergency department visits and hospital readmissions.
Time frame: 3 months and 12 months
Anonymized and de-identified MRI scans will be processed using MIPAV55 v.7.3.0 and Oxford Centre for Functional MRI of the Brain (FMRIB) Software Library (FSL) v.5.0 medical image processing programs. Scans will be corrected for intensity non-uniformity and transformed into a common image space to adjust for variations in head size and orientation. Skull stripping will be performed. Automated and semi-automated techniques will be used to determine whole-brain volumes from T1-weighted images for analysis of macrostructural brain integrity, as well as FA and MD measures from diffusion-weighted images for analysis of microstructural brain integrity. Brain volumes will be corrected for total intracranial volume to account for head size. Reasons for non-completion of MRI scanning will be recorded. Patients will be used as their own controls over time using a within-subjects design.
Contact information is provided by the study sponsor or research team.
Dr. Gordon Boyd
Other
Identifying Neurocognitive Outcomes and Cerebral Oxygenation in Critically Ill Adults on Acute Kidney Replacement Therapy in the Intensive Care Unit
Acronym: INCOGNITOAKI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06411561
Alzheimer Disease, Alzheimer's Disease
Seattle, Washington, United States
View Trial DetailsNCT04742673
Cognition Disorders, Cognitive Dysfunction
Nashville, Tennessee, United States
View Trial DetailsNCT03098459
Alzheimer Disease, Alzheimer; Early Onset
Nashville, Tennessee, United States
View Trial DetailsNCT03972384
Cognition Disorders, Cognitive Dysfunction
Columbus, Ohio, United States
View Trial Details